AtriCure, Inc. (NASDAQ: ATRC) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $2.8B. The Maz Rating grades it against the other companies in its sector.
AtriCure, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $55.02, AtriCure, Inc. trades at 183.6x trailing earnings, 4.8x sales and 5.1x book value, with an EV/EBITDA of 69.3. Over the last twelve months it generated about $587M of revenue and $15M of net income. It runs a gross margin of 76.6%, an operating margin of 3.1% and a net margin of 2.5%. It shows return on equity of 2.9%, return on invested capital of 2.6% and a free cash flow yield of 1.9%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 4.33. Over the past 52 weeks the share price ranged from $25.36 to $66.02, with a beta of 1.21.
AtriCure, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 17 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.